Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat

Özaçmak, Veysel Haktan; Sayan, Hale

doi:10.3748/wjg.v13.i4.538

Cited by 17 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have shown that A1 receptor mediates cholinergic nerve activity in ileum and the impaired cholinergic neurotransmission may mediate altered motility during inflammation (33,67,130). One study has demonstrated a beneficial effect of A1 receptor agonist in ischemic intestinal injury (103). As more information regarding the underlying physiology of the A1 receptors is gathered, further studies are required to define its role in intestinal inflammation if therapeutic targets are to be developed.…”

Section: A1 Receptormentioning

confidence: 98%

Purinergic receptors in gastrointestinal inflammation

Kolachala

Bajaj²,

Chalasani³

et al. 2008

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Purinergic receptors comprise a family of transmembrane receptors that are activated by extracellular nucleosides and nucleotides. The two major classes of purinergic receptors, P1 and P2, are expressed widely in the gastrointestinal tract as well as immune cells. The purinergic receptors serve a variety of functions from acting as neurotransmitters, to autocoid and paracrine signaling, to cell activation and immune response. Nucleosides and nucleotide agonist of purinergic receptors are released by many cell types in response to specific physiological signals, and their levels are increased during inflammation. In the past decade, the advent of genetic knockout mice and the development of highly potent and selective agonists and antagonists for the purinergic receptors have significantly advanced the understanding of purinergic receptor signaling in health and inflammation. In fact, agonist/antagonists of purinergic receptors are emerging as therapeutic modalities to treat intestinal inflammation. In this article, the distribution of the purinergic receptors in the gastrointestinal tract and their physiological and pathophysiological role in intestinal inflammation will be reviewed.

show abstract

Section: A1 Receptormentioning

confidence: 98%

Purinergic receptors in gastrointestinal inflammation

Kolachala

Bajaj²,

Chalasani³

et al. 2008

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

show abstract

“…However, adenosine is effective in protecting the intestinal microvasculature from the injurious effects of ischemia-reperfusion (Grisham et al, 1989), perhaps via A 1 receptors (Özaçmak and Sayan, 2007). It was concluded in another study that adenosine acts by modulating the inflammatory response evoked by intestinal reperfusion (Kaminski and Proctor, 1992).…”

Section: H Intestinal Vesselsmentioning

confidence: 99%

Purinergic Signaling and Blood Vessels in Health and Disease

2013

View full text Add to dashboard Cite

“…There is evidence for an anti-inflammatory role for A 1 R in lung 5 , liver 15 , kidney 16 , heart 17 , intestine 18 and skeletal muscle. 19 However, other studies have suggested that A 1 R antagonism has beneficial effects in lung and heart IR models.…”

Section: Discussionmentioning

confidence: 99%

Adenosine A1 Receptor Activation Attenuates Lung Ischemia-Reperfusion Injury

Fernández

Sharma

Krön

et al. 2012

C101. Transplant and Ischemia and Reperfusion Related Lung Injury

View full text Add to dashboard Cite

Objectives-Ischemia-reperfusion injury significantly contributes to morbidity and mortality in lung transplant patients. Currently no therapeutic agents are clinically available to prevent ischemia-reperfusion injury, and treatment strategies are limited to maintaining oxygenation and lung function. Adenosine can modulate inflammatory activity and injury via binding to various adenosine receptors, but the role of adenosine A 1 receptor in ischemia-reperfusion injury and inflammation is not well understood. This study tests the hypothesis that selective, exogenous activation of A 1 receptor is anti-inflammatory and attenuates lung ischemia-reperfusion injury.Methods-Wild-type and A 1 receptor knockout mice underwent 1 hour left lung ischemia and 2 hours reperfusion using an in vivo hilar-clamp model. An A 1 receptor agonist, CCPA, was administered 5 minutes before ischemia. After reperfusion, lung function was evaluated by measuring airway resistance, pulmonary compliance and pulmonary artery pressure. Wet/dry weight ratio was used to assess edema. Myeloperoxidase and cytokine levels in bronchoalveolar lavage fluid were measured to determine neutrophil infiltration and inflammation.Results-In wild-type animals, CCPA significantly improved lung function and attenuated edema, cytokine expression and myeloperoxidase levels compared to vehicle-treated mice after ischemia-reperfusion. Lung ischemia-reperfusion injury was similar between A 1 receptor knockout and wild-type mice, but CCPA had no effects in A 1 receptor knockout mice. In vitro treatment of neutrophils with CCPA significantly reduced chemotaxis.Conclusions-Exogenous A 1 receptor activation improves lung function and decreases inflammation, edema and neutrophil chemotaxis after ischemia-reperfusion. These results suggest a potential therapeutic application for A 1 receptor agonists for the prevention of lung ischemiareperfusion injury after transplantation.

show abstract

Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat

Cited by 17 publications

References 52 publications

Purinergic receptors in gastrointestinal inflammation

Purinergic receptors in gastrointestinal inflammation

Purinergic Signaling and Blood Vessels in Health and Disease

Adenosine A1 Receptor Activation Attenuates Lung Ischemia-Reperfusion Injury

Contact Info

Product

Resources

About